ornithylaspartate has been researched along with Cirrhosis, Liver in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (9.09) | 18.2507 |
| 2000's | 9 (27.27) | 29.6817 |
| 2010's | 19 (57.58) | 24.3611 |
| 2020's | 2 (6.06) | 2.80 |
| Authors | Studies |
|---|---|
| Aliwa, B; Bourgeois, B; Horvath, A; Madl, T; Stadlbauer, V; Traub, J | 1 |
| Arias, N; Hadjihambi, A; Jalan, R; Sheikh, M | 1 |
| Dahale, AS; Sachdeva, S; Sharma, BC; Srivastava, S; Varakanahalli, S | 1 |
| Gluud, LL; Goh, ET; Morgan, MY; Sidhu, SS; Stokes, CS; Vilstrup, H | 1 |
| Abdo-Francis, JM; Alla, SN; Camacho-Aguilera, J; Higuera-de-la-Tijera, F; Jiménez-Ponce, F; Pérez-Hernández, JL; Salas-Gordillo, F; Servín-Caamaño, AI | 1 |
| Butterworth, RF | 2 |
| Kircheis, G; Lüth, S | 1 |
| Butterworth, RF; McPhail, MJW | 1 |
| Alsahhar, JS; Rahimi, RS | 1 |
| Bai, M; Fan, D; Han, G; Qi, X; Yang, Z | 1 |
| Kutepov, DE; Pasechnik, IN; Sal'nikov, PS; Vershinina, MG | 1 |
| Manzhaliĭ, EH; Moĭseienko, VO; Nykula, TD; Solonovych, OS | 1 |
| Achermann, P; Amodio, P; Angeli, P; Garrido, M; Montagnese, S; Raduazzo, D; Skorucak, J; Spinelli, G; Turco, M | 1 |
| Bak-Bol, A; Cook, NA; Cox, IJ; Crossey, MM; Dhanjal, NS; Fitzpatrick, JA; Grover, VP; McPhail, MJ; Morgan, MY; Saxby, BK; Southern, L; Taylor-Robinson, SD; Waldman, AD; Williams, R; Wylezinska-Arridge, M | 1 |
| Ahmad, I; Alam, A; Butt, AK; Dilshad, A; Khan, AA; Malik, K; Sarwar, S; Shafqat, F | 1 |
| Ferenci, P; Gangl, A; König, F; Mittermaier, C; Peck-Radosavljevic, M; Schmid, M | 1 |
| Krüger-Jansen, C; Lambert-Baumann, J; Oehler, G; Ong, JP; Younossi, ZM | 1 |
| Hasan, I; Ndraha, S; Simadibrata, M | 1 |
| Abbas, Z; Abid, S; Hamid, S; Islam, M; Jafri, W; Mumtaz, K; Shah, HA | 1 |
| Blanco Vela, CI; Poo Ramírez, JL | 1 |
| Fehérvári, I; Gerlei, Z; Görög, D; Kóbori, L; Nemes, B | 1 |
| Dahl, Sv; Häussinger, D; Kircheis, G; Wettstein, M | 1 |
| Gregor, M; Hass, HG; Hösl, F; Kaiser, S; Nägele, T; Seeger, U | 1 |
| Chen, CH; Chen, MF; Gao, XC; Li, RC | 1 |
| Bueverov, AO; Nadinskaia, MIu; Podymova, SD | 1 |
| Gladisch, R; Hagmüller, E; Holm, E; Kortsik, C; Leweling, H; Staedt, U | 1 |
| Berndt, H; Buchner, M; Görtelmeyer, R; Held, C; Hendricks, R; Kircheis, G; Krüger, B; Kuklinski, B; Meister, H; Nilius, R; Otto, HJ; Rink, C; Rösch, W; Stauch, S | 1 |
| Koczorek, M | 1 |
| Dicheva, DT; Iakovenko, EI; Lebedeva, EG; Maev, IV; V'iuchnova, ES | 1 |
9 review(s) available for ornithylaspartate and Cirrhosis, Liver
| Article | Year |
|---|---|
Hepatic encephalopathy: a critical current review.
Topics: Albumins; Ammonia; Anti-Bacterial Agents; Bile Acids and Salts; Brain; Brain Edema; Cognitive Dysfunction; Dipeptides; Energy Metabolism; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Ornithine; Portasystemic Shunt, Surgical; Prognosis; Psychometrics; Severity of Illness Index; Synaptic Transmission | 2018 |
L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Topics: Dipeptides; Hepatic Encephalopathy; Humans; Liver Cirrhosis; Quality of Life; Randomized Controlled Trials as Topic | 2018 |
Pharmacokinetic and Pharmacodynamic Properties of L-Ornithine L-Aspartate (LOLA) in Hepatic Encephalopathy.
Topics: Ammonia; Animals; Brain; Dipeptides; Glutamic Acid; Glutamine; Hepatic Encephalopathy; Humans; Liver; Liver Cirrhosis; Muscles; Rats; Signal Transduction | 2019 |
L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses.
Topics: Ammonia; Dipeptides; Hepatic Encephalopathy; Humans; Liver; Liver Cirrhosis; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Secondary Prevention; Systematic Reviews as Topic; Treatment Outcome | 2019 |
Updates on the pathophysiology and therapeutic targets for hepatic encephalopathy.
Topics: Amino Acids, Aromatic; Amino Acids, Branched-Chain; Ammonia; Dipeptides; Fecal Microbiota Transplantation; Frailty; Gastrointestinal Agents; Gastrointestinal Microbiome; Glycerol; Hepatic Encephalopathy; Humans; Hypertension, Portal; Lactulose; Liver Cirrhosis; Ornithine; Phenylbutyrates; Polyethylene Glycols; Probiotics; Rifaximin; Trace Elements; Zinc | 2019 |
Beneficial effects of L-ornithine L-aspartate for prevention of overt hepatic encephalopathy in patients with cirrhosis: a systematic review with meta-analysis.
Topics: Clinical Trials as Topic; Dipeptides; Hepatic Encephalopathy; Humans; Liver Cirrhosis; Treatment Outcome | 2020 |
l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials.
Topics: Ammonia; Dipeptides; Hepatic Encephalopathy; Humans; Liver Cirrhosis; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
[Hepatic encephalopathy and liver transplantation].
Topics: Ammonia; Anti-Infective Agents; Colon; Dipeptides; Disaccharides; End Stage Liver Disease; Evidence-Based Medicine; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Hungary; Hydrogen-Ion Concentration; Lactobacillus; Lactulose; Laxatives; Liver Cirrhosis; Liver Transplantation; Metronidazole; Neomycin; Rifamycins; Rifaximin; Severity of Illness Index; Sugar Alcohols; Systemic Inflammatory Response Syndrome; Treatment Outcome | 2012 |
Clinical efficacy of L-ornithine-L-aspartate in the management of hepatic encephalopathy.
Topics: Ammonia; Dipeptides; Hepatic Encephalopathy; Humans; Liver Cirrhosis; Muscular Diseases; Severity of Illness Index | 2002 |
12 trial(s) available for ornithylaspartate and Cirrhosis, Liver
| Article | Year |
|---|---|
Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver: a double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo.
Topics: Adult; Ammonia; Biomarkers; Chi-Square Distribution; Dipeptides; Double-Blind Method; Female; Flicker Fusion; Hepatic Encephalopathy; Humans; India; Kaplan-Meier Estimate; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neuropsychological Tests; Odds Ratio; Psychometrics; Recurrence; Risk Factors; Secondary Prevention; Sickness Impact Profile; Tertiary Care Centers; Time Factors; Treatment Outcome | 2018 |
Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding.
Topics: Acute Disease; Adult; Dipeptides; Double-Blind Method; Esophageal and Gastric Varices; Female; Gastrointestinal Agents; Gastrointestinal Hemorrhage; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Rifaximin | 2018 |
L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy.
Topics: Adult; Aged; Ammonia; Cognition; Dipeptides; Female; Health Status Indicators; Hepatic Encephalopathy; Humans; Hyperammonemia; Infusions, Intravenous; Liver Cirrhosis; Male; Middle Aged; Postprandial Period | 2008 |
A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis.
Topics: Aged; Ammonia; Biopsy, Needle; Dipeptides; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Hepatic Encephalopathy; Humans; Immunohistochemistry; Infusions, Intravenous; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Pilot Projects; Postural Balance; Psychometrics; Reference Values; Risk Assessment; Sensation Disorders; Severity of Illness Index; Statistics, Nonparametric; Survival Rate; Treatment Outcome | 2010 |
Oral L-ornithine-L-aspartate improves health-related quality of life in cirrhotic patients with hepatic encephalopathy: an open-label, prospective, multicentre observational study.
Topics: Administration, Oral; Adult; Aged; Dipeptides; Female; Hepatic Encephalopathy; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Quality of Life | 2011 |
The effect of L-ornithine L-aspartate and branch chain amino acids on encephalopathy and nutritional status in liver cirrhosis with malnutrition.
Topics: Adult; Aged; Albumins; Amino Acids, Branched-Chain; Ammonia; Dietary Proteins; Dipeptides; Double-Blind Method; Female; Hepatic Encephalopathy; Humans; Liver Cirrhosis; Male; Malnutrition; Middle Aged; Nutritional Status; Young Adult | 2011 |
Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy.
Topics: Anti-Infective Agents; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrointestinal Agents; Glucose; Hepatic Encephalopathy; Humans; Infusions, Intravenous; Lactulose; Length of Stay; Liver Cirrhosis; Male; Metronidazole; Middle Aged; Prospective Studies; Treatment Outcome | 2011 |
[Therapeutic effect of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy].
Topics: Dipeptides; Female; Hepatic Encephalopathy; Humans; Infusions, Intravenous; Liver Cirrhosis; Male; Middle Aged | 2005 |
[The treatment of hepatic encephalopathy with Hepa-Mertz].
Topics: Ammonia; Biomarkers; Chronic Disease; Dipeptides; Hepatic Encephalopathy; Humans; Liver Cirrhosis; Psychomotor Performance; Time Factors | 1995 |
Effects of ornithine aspartate on plasma ammonia and plasma amino acids in patients with cirrhosis. A double-blind, randomized study using a four-fold crossover design.
Topics: Adult; Amino Acids; Ammonia; Blood Glucose; Dipeptides; Double-Blind Method; Female; Humans; Insulin; Liver Cirrhosis; Male; Middle Aged; Urea | 1993 |
Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.
Topics: Adult; Aged; Ammonia; Dipeptides; Double-Blind Method; Female; Hepatic Encephalopathy; Humans; Infusions, Intravenous; Liver Cirrhosis; Male; Mental Health; Middle Aged; Placebos; Veins | 1997 |
[The response to combined therapy of hepatic encephalopathy in patients with hepatic cirrhosis].
Topics: Adult; Dipeptides; Drug Therapy, Combination; Female; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged | 2002 |
12 other study(ies) available for ornithylaspartate and Cirrhosis, Liver
| Article | Year |
|---|---|
Oral Intake of L-Ornithine-L-Aspartate Is Associated with Distinct Microbiome and Metabolome Changes in Cirrhosis.
Topics: Dipeptides; Humans; Liver Cirrhosis; Metabolome; Microbiota; Retrospective Studies | 2022 |
L-Ornithine L-Aspartate (LOLA) for the Treatment of Hepatic Encephalopathy in Cirrhosis: Novel Insights and Translation to the Clinic.
Topics: Astrocytes; Dipeptides; Hepatic Encephalopathy; Humans; Hyperammonemia; Liver Cirrhosis; Translational Research, Biomedical | 2019 |
[Comparative effectiveness of different treatment methods of liver failure].
Topics: Comparative Effectiveness Research; Dipeptides; Extracorporeal Circulation; Female; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Liver Failure; Male; Middle Aged; Monitoring, Physiologic; Plasma Exchange; Sorption Detoxification; Treatment Outcome | 2014 |
[Pathogenesis, diagnosis and treatment of hepatic encephalopathies in patients with liver cirrhosis].
Topics: Adult; Aged; Ammonia; Citric Acid Cycle; Dipeptides; Event-Related Potentials, P300; Female; Hepatic Encephalopathy; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Protective Agents; Severity of Illness Index | 2014 |
Vigilance and wake EEG architecture in simulated hyperammonaemia: a pilot study on the effects of L-Ornithine-L-Aspartate (LOLA) and caffeine.
Topics: Adult; Brain; Caffeine; Dipeptides; Electroencephalography; Female; Hepatic Encephalopathy; Humans; Hyperammonemia; Liver Cirrhosis; Male; Middle Aged; Neuropsychological Tests; Pilot Projects; Wakefulness | 2016 |
A longitudinal study of patients with cirrhosis treated with L-ornithine L-aspartate, examined with magnetization transfer, diffusion-weighted imaging and magnetic resonance spectroscopy.
Topics: Adult; Aged; Brain; Cognition; Diffusion Magnetic Resonance Imaging; Dipeptides; Female; Hepatic Encephalopathy; Humans; Liver Cirrhosis; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Middle Aged; Psychometrics | 2017 |
Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy.
Topics: Administration, Oral; Ammonia; Dipeptides; Glutamine; Hepatic Encephalopathy; Humans; Hyperammonemia; Liver Cirrhosis; Quality of Life; Severity of Illness Index; Treatment Outcome; Urea | 2011 |
[Because hepatic encephalopathy is a frequent contributing factor. Patients with liver cirrhosis are poorer drivers].
Topics: Accidents, Traffic; Ammonia; Dipeptides; Hepatic Encephalopathy; Humans; Liver Cirrhosis | 2003 |
[Cirrhotic liver gives up in breaking up of ammonia. Poison for the brain].
Topics: Ammonia; Clinical Trials as Topic; Dipeptides; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Quality of Life; Self-Help Groups | 2004 |
[Detection of subclinical and overt hepatic encephalopathy and treatment control after L-ornithine-L-aspartate medication by magnetic resonance spectroscopy ((1)H-MRS)].
Topics: Adult; Ammonia; Brain; Choline; Combined Modality Therapy; Creatinine; Diet, Protein-Restricted; Dipeptides; Energy Metabolism; Female; Follow-Up Studies; Glutamic Acid; Glutamine; Hepatic Encephalopathy; Humans; Infusions, Intravenous; Inositol; Liver Cirrhosis; Magnetic Resonance Spectroscopy; Male; Middle Aged; Neuropsychological Tests; Pilot Projects; Prospective Studies; Reference Values; Statistics as Topic | 2005 |
[Chronic liver diseases. Hepatic encephalopathy too frequently overlooked?].
Topics: Ammonia; Dipeptides; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Neomycin | 2000 |
[Chronic liver diseases. The nihilism has gone].
Topics: Amantadine; Antioxidants; Antiviral Agents; Chronic Disease; Dipeptides; Drug Therapy, Combination; Flumazenil; GABA Modulators; Hepatic Encephalopathy; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Diseases; Pentoxifylline; Phosphodiesterase Inhibitors; Prospective Studies; Protective Agents; Ribavirin; Silymarin | 2001 |